• Recruiting

NCT03702725: Phase 1: Study of Ibrutinib in Combination With Revlimid/Dexamethasone in RRMM Myeloma

NCT03702725: Phase 1: Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma


ibrutinib

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma


Sponsor:

Alliance Foundation Trials, LLC.


Collaborator:

Pharmacyclics LLC.


Multiple Locations


This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.

 

ClinicalTrials.gov Identifier: NCT03702725


Official Title: A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma

First Posted : October 11, 2018


Click here to see details on ClinicalTrials.gov

 

Drug: Ibrutinib

Drug: Lenalidomide

Drug: Dexamethasone

 



Posts Archive